All In Biotech

Drug Trial Radar · NCT07204457

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,123 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,123

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Sep 2026

Study completion Jun 2027

Sponsor

Lead sponsor
EyeGene Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BMI Korea
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

Conditions

  • Meningococcal Infections

Interventions

  • EG-MCV4Biological

    single intramuscular dose on Day 0

  • MenveoBiological

    single intramuscular dose on Day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SeroresponseTime frame: 28 days after the vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Eunpyeong St.Mary's Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.